Advanced Cell Technology Secures Approval From Data Safety Monitoring Board to Complete Third Patient Cohort in All Three Clinical Trials

Published: Jul 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT”) (OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).

Help employers find you! Check out all the jobs and post your resume.

Back to news